Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Pacira BioSciences

< Previous 1 2 3 Next >
Pacira BioSciences Reports Fourth Quarter and Full-Year 2024 Financial Results
From Pacira BioSciences
Via GlobeNewswire
Tickers PCRX
Pacira BioSciences Acquires Remaining Equity Stake of GQ Bio
From Pacira BioSciences
Via GlobeNewswire
Tickers PCRX
Pacira BioSciences to Participate in Fireside Chat at Two Healthcare Conferences in March
From Pacira BioSciences
Via GlobeNewswire
Tickers PCRX
Pacira to Report 2024 Financial Results on Thursday February 27, 2025
From Pacira BioSciences
Via GlobeNewswire
Tickers PCRX
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Pacira BioSciences
Via GlobeNewswire
Tickers PCRX
Pacira Announces Updates to Board of Directors
From Pacira BioSciences
Via GlobeNewswire
Tickers PCRX
Pacira BioSciences Strengthens Executive Leadership Team with Two Key Appointments
From Pacira BioSciences
Via GlobeNewswire
Tickers PCRX
Pacira Announces New Five-Year Objectives to Accelerate Transition into an Innovative Biopharmaceutical Organization
From Pacira BioSciences
Via GlobeNewswire
Tickers PCRX
Pacira BioSciences Receives FDA 510k Clearance for New iovera° SmartTip to Manage Chronic Low Back Pain via Long-lasting Medial Branch Nerve Block
From Pacira BioSciences
Via GlobeNewswire
Tickers PCRX
Pacira BioSciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference
From Pacira BioSciences
Via GlobeNewswire
Tickers PCRX
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
From Pacira BioSciences
Via GlobeNewswire
Tickers PCRX
Pacira Awarded New U.S. Patent Covering EXPAREL Composition
From Pacira BioSciences
Via GlobeNewswire
Tickers PCRX
Pacira Announces 104-Week Safety and Efficacy Data Following Local Administration of PCRX-201 for Moderate to Severe Osteoarthritis of the Knee
From Pacira BioSciences
Via GlobeNewswire
Tickers PCRX
Pacira BioSciences to Participate in Fireside Chat at Two Upcoming Healthcare Conferences
From Pacira BioSciences
Via GlobeNewswire
Tickers PCRX
Pacira BioSciences Reports Third Quarter 2024 Financial Results
From Pacira BioSciences
Via GlobeNewswire
Tickers PCRX
Centers for Medicare and Medicaid Services (CMS) Establishes Additional Payment for iovera in Outpatient Settings
From Pacira BioSciences
Via GlobeNewswire
Tickers PCRX
Pacira to Report Third Quarter 2024 Financial Results on Wednesday November 6, 2024
From Pacira BioSciences
Via GlobeNewswire
Tickers PCRX
Pacira BioSciences Appoints Shawn Cross as Chief Financial Officer
From Pacira BioSciences
Via GlobeNewswire
Tickers CYTH PCRX
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
From Pacira BioSciences
Via GlobeNewswire
Tickers PCRX
Pacira BioSciences Announces New Product-Specific J-Code for EXPAREL Effective January 1, 2025
From Pacira BioSciences
Via GlobeNewswire
Tickers PCRX
Pacira Announces the Presentation of 104-Week Safety and Efficacy Data Following Local Administration of PCRX-201 for Moderate to Severe Osteoarthritis of the Knee
From Pacira BioSciences
Via GlobeNewswire
Tickers PCRX
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
From Pacira BioSciences
Via GlobeNewswire
Tickers PCRX
Pacira BioSciences Comments on Ruling on EXPAREL Patent Litigation from U.S. District Court for the District of New Jersey
From Pacira BioSciences
Via GlobeNewswire
Tickers PCRX
Pacira BioSciences Reports Second Quarter 2024 Financial Results
From Pacira BioSciences
Via GlobeNewswire
Tickers PCRX
Pacira to Report Second Quarter 2024 Financial Results on Tuesday July 30, 2024
From Pacira BioSciences
Via GlobeNewswire
Tickers PCRX
Centers for Medicare and Medicaid Propose New Reimbursement for EXPAREL in All Outpatient Surgical Environments Beginning January 1, 2025
From Pacira BioSciences
Via GlobeNewswire
Tickers PCRX
Pacira BioSciences to Participate in Fireside Chat at the 2024 Jefferies Global Healthcare Conference
From Pacira BioSciences
Via GlobeNewswire
Tickers PCRX
Pacira BioSciences, Inc. Announces Pricing of $250.0 Million Aggregate Principal Amount of 2.125% Convertible Senior Notes due 2029
From Pacira BioSciences
Via GlobeNewswire
Tickers PCRX
Pacira BioSciences, Inc. Announces Proposed Offering of $250.0 Million Aggregate Principal Amount of Convertible Senior Notes
From Pacira BioSciences
Via GlobeNewswire
Tickers PCRX
Pacira BioSciences Reports First Quarter 2024 Financial Results and Announces $150 Million Share Repurchase program
From Pacira BioSciences
Via GlobeNewswire
Tickers PCRX
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.